Synthetic biomedical data generation in support of In Silico Clinical Trials
Frontiers in Big Data, 2023 Living in the era of Big Data, one may advocate that the additional synthetic generation of data is redundant. However, to be able to truly say whether it is valid or not, one needs to focus more on the meaning and quality of data than on the quantity ...
Alena Simalatsar +2 more
doaj +1 more source
The benefits of in silico modeling to identify possible small-molecule drugs and their off-target interactions [PDF]
, 2018 Accepted for publication in a future issue of Future Medicinal Chemistry.The research into the use of small molecules as drugs continues to be a key driver in the development of molecular databases, computer-aided drug design software and collaborative ...
Blomberg N +6 more
core +2 more sources
Optimizing radiation therapy treatments by exploring tumour ecosystem dynamics in-silico [PDF]
, 2019 In this contribution, we propose a system-level compartmental population dynamics model of tumour cells that interact with the patient (innate) immune system under the impact of radiation therapy (RT).
Fellermann, Harold, Scheidegger, Stephan
core +1 more source
Bayesian Augmented Clinical Trials in TB Therapeutic Vaccination
Frontiers in Medical Technology, 2021 We propose a Bayesian hierarchical method for combining in silico and in vivo data onto an augmented clinical trial with binary end points. The joint posterior distribution from the in silico experiment is treated as a prior, weighted by a measure of ...
Dimitrios Kiagias +4 more
doaj +1 more source
Continuous glucose monitoring sensors: Past, present and future algorithmic challenges [PDF]
, 2016 Continuous glucose monitoring (CGM) sensors are portable devices that allow measuring and visualizing the glucose concentration in real time almost continuously for several days and are provided with hypo/hyperglycemic alerts and glucose trend ...
Facchinetti, Andrea
core +2 more sources
New Microbes and New Infections, 2020 Randomized clinical trials are not relevant for infectious disease outbreaks due to a new pathogen, for which public health decisions have to be made urgently.
P. Gautret, D. Raoult
doaj +1 more source
In silico clinical trials: concepts and early adoptions
Briefings in Bioinformatics, 2018 Abstract Innovations in information and communication technology infuse all branches of science, including life sciences. Nevertheless, healthcare is historically slow in adopting technological innovation, compared with other industrial sectors. In recent years, new approaches in modelling and simulation have started to provide important
Francesco Pappalardo 0001 +3 more
openaire +2 more sources
Repurposing cancer drugs, batimastat and marimastat, to inhibit the activity of a group I metalloprotease from the venom of the Western Diamondback rattlesnake, Crotalus atrox [PDF]
, 2020 Snakebite envenomation causes over 140,000 deaths every year predominantly in developing countries. As a result, it is one of the most lethal neglected tropical diseases.
Bicknell, Andrew B. +12 more
core +1 more source
In silico clinical trials for anti-aging therapies
Aging, 2019 Therapeutic strategies targeting the hallmarks of aging can be broadly grouped into four categories, namely systemic (blood) factors, metabolic manipulation (diet regimens and dietary restriction mimetics), suppression of cellular senescence (senolytics), and cellular reprogramming, which likely have common characteristics and mechanisms of action.
Menéndez Menéndez, Javier Abel +6 more
openaire +6 more sources
Identification of hepta-histidine as a candidate drug for Huntington's disease by in silico-in vitro- in vivo-integrated screens of chemical libraries. [PDF]
, 2016 We identified drug seeds for treating Huntington's disease (HD) by combining in vitro single molecule fluorescence spectroscopy, in silico molecular docking simulations, and in vivo fly and mouse HD models to screen for inhibitors of abnormal ...
Chen, Xigui +17 more
core +2 more sources